Understand the Total Market Size and Treatment Opportunities for Biomarkers
The development of biomarker-driven therapies continues to be a major trend in oncology. Because biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
DRG Epidemiology's coverage of ALK-mutated tumors comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ALK-mutated tumors for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's ALK-mutated tumors forecast will answer the following questions:
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following ALK-mutated tumors subpopulations:
Note: Coverage may vary by country.
You need biomarker epidemiology data you can trust in order to: